Genentech and Parvus Therapeutics Collaborate on Autoimmune Diseases
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 5 (Table of Contents)
Published: 22 May-2019
DOI: 10.3833/pdr.v2019.i5.2426 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In an effort to expand its autoimmune pipeline, Genentech has agreed to collaborate with Parvus Therapeutics to develop and commercialise therapeutics for the treatment of inflammatory bowel disease, autoimmune liver diseases, and celiac disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018